



Study on the impact of advancing global oncology towards equity in precision prevention and medicine

Timothy Babatunde¹, Emmanson Emmanson Godswill², Usiju Medugu Ndai³, Anthonia B Ojomo⁴, Lawal Sodiq⁵

¹ Department of Human Physiology, Delta State University, Nigeria

² Lecturer, Department of Nursing Sciences, Sacred Heart College of Nursing Sciences, Abeokuta, Nigeria

³ Department of pharmacology, University of Maiduguri, Nigeria

⁴ Department of Pharmacy, Universite De Parakou, Benin

⁵ Department of Human Anatomy, University of ilorin, Kwara state, Nigeria

Abstract

Advancements in global oncology have revolutionized the landscape of cancer prevention and treatment, ushering in an era of precision medicine. However, as breakthroughs occur, the issue of equitable access to these innovations becomes increasingly critical. This paper explores the profound impact of advancing global oncology towards achieving equity in precision prevention and medicine. By examining the intersection of technology, healthcare infrastructure, and socio-economic factors, we assess both the progress made and the challenges that lie ahead in ensuring that all individuals, regardless of their geographic location or socio-economic status, can benefit from the latest developments in cancer care. Through comprehensive analysis and case studies, this paper elucidates the multifaceted strategies required to bridge the gap in access to precision oncology, emphasizing the importance of collaborative efforts among stakeholders across the globe. Ultimately, this exploration underscores the imperative of prioritizing equity as we navigate the evolving landscape of cancer prevention and treatment, striving towards a future where every individual receives the personalized care they deserve.

Keywords: Impact, advancing, global oncology, equity, precision, prevention, medicine

Introduction

Cancer remains a significant global health challenge, with a disproportionate burden on Low- and Middle-Income Countries (LMICs). The disparity in cancer outcomes between high-income countries (HICs) and LMICs is striking, reflecting variations in healthcare infrastructure, access to treatment, and socio-economic factors. Precision prevention and medicine, an approach tailoring prevention and treatment strategies to individual characteristics, have emerged as promising avenues in oncology. However, the equitable implementation of precision approaches remains a challenge, particularly in LMICs. This paper aims to investigate how advancements in global oncology can contribute to achieving equity in cancer care by leveraging precision approaches in LMICs.

Literature Review

Cancer is a significant global health concern, with a disproportionate burden falling on Low- and Middle-Income Countries (LMICs). The advancement of global oncology holds promise in addressing this disparity by promoting equity in precision prevention and medicine. This literature review synthesizes findings from scientific articles to elucidate the impact of advancing global oncology towards achieving equity in precision approaches, particularly in LMICs.

Global Cancer Burden and Disparities

- Ferlay J, *et al.* (2019) ^[2]. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.*

This seminal study by Ferlay and colleagues provides comprehensive insights into the global cancer burden. It highlights the staggering disparities in cancer incidence and

mortality between HICs and LMICs, underscoring the urgent need for equitable interventions.

Precision Oncology and Personalized Medicine:

- Schwaederle M, *et al.* (2016) ^[5]. *Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials.*
- Schwaederle *et al.*'s meta-analysis examines the impact of precision medicine across various cancer types. The study demonstrates improved outcomes and higher response rates in patients receiving precision treatments, highlighting the potential of personalized approaches in oncology.

Challenges in LMICs:

- Chokunonga E, *et al.* (2016) ^[1]. *Cancer Survival in Africa, Asia, the Caribbean and Central America (SurvCan).*

This multi-national study sheds light on the challenges of cancer survival in LMICs. It identifies barriers such as limited access to healthcare facilities, diagnostic technologies, and essential medications, hindering timely diagnosis and treatment initiation.

Role of Technology and Innovation:

- Rodin D, *et al.* (2016) ^[4]. *Innovation for global cancer care: Lessons learnt from the Africa Oxford Cancer Foundation.*

Rodin and colleagues discuss the role of innovation in addressing cancer care disparities, focusing on initiatives like the Africa Oxford Cancer Foundation. The article emphasizes the importance of leveraging technology and

collaborative partnerships to improve cancer outcomes in resource-limited settings.

Community-Based Interventions:

- Loehrer PJ, *et al.* (2017) ^[3]. *Effective Partnerships in Cancer Care: A Community Oncology Perspective.*

This article explores the efficacy of community-based partnerships in delivering cancer care, particularly in underserved regions. It underscores the significance of engaging local healthcare providers and community leaders to enhance access to precision oncology services.

The reviewed literature underscores the imperative of advancing global oncology towards achieving equity in precision prevention and medicine. By addressing disparities in cancer burden, embracing precision approaches, overcoming challenges in LMICs, leveraging technology and innovation, and fostering community-based interventions, stakeholders can collectively strive towards equitable cancer care on a global scale.

Methodology

This research employs a multi-faceted approach to investigate the impact of advancing global oncology towards achieving equity in precision prevention and medicine. The methodology consists of a comprehensive literature review, supplemented by case studies and qualitative data analysis.

Literature Review

- A systematic search of scientific databases such as PubMed, Google Scholar, and Web of Science was conducted to identify relevant peer-reviewed articles, reports, and studies related to global oncology, precision medicine, cancer disparities, and healthcare access in LMICs.
- Keywords including "global oncology," "precision medicine," "cancer burden," "LMICs," and "equity" were used to refine the search and ensure comprehensive coverage of the literature.
- Selected articles were critically evaluated to extract key findings, identify emerging themes, and synthesize relevant information pertinent to the research question.

Case Studies

- Case studies were included to provide real-world examples and insights into the implementation of precision approaches in LMICs.
- Cases were selected based on their relevance to the research topic and their potential to illustrate challenges and opportunities in advancing global oncology towards equity.
- Information from case studies was analyzed qualitatively to identify common patterns, barriers, and successful strategies in the implementation of precision prevention and medicine.

Data Collection and Analysis

- Data collection primarily involved gathering information from peer-reviewed articles, reports, and relevant documents identified through the literature review process.
- Qualitative data analysis techniques such as thematic analysis were employed to identify recurring themes, patterns, and variations within the collected data.

- Data analysis focused on synthesizing information from diverse sources to develop a comprehensive understanding of the impact of advancing global oncology on equity in precision prevention and medicine.

This methodological approach enables a nuanced exploration of the research topic, drawing on diverse sources of evidence to inform discussions on the challenges and opportunities in promoting equitable access to precision oncology interventions in LMICs.

Results

Challenges and Opportunities for Implementing Precision Prevention and Medicine in LMICs:

Limited Healthcare Infrastructure and Resources

- **Challenges:** Many LMICs face significant challenges in healthcare infrastructure, including limited access to diagnostic tools, treatment facilities, and trained healthcare professionals.
- **Opportunities:** Despite these challenges, innovative solutions such as mobile health technologies and telemedicine are emerging to bridge the gap in healthcare access. For example, initiatives like the African Oncology Consortium (AORTIC) leverage telemedicine to provide remote consultations and training for healthcare providers in underserved regions.

Cost and Affordability

- **Challenges:** The high cost of precision oncology interventions, including genomic testing and targeted therapies, poses a barrier to access for patients in LMICs, where healthcare expenditure is limited.
- **Opportunities:** Efforts to reduce costs through partnerships with pharmaceutical companies, technology transfer agreements, and the development of low-cost diagnostic tools offer promising avenues for expanding access to precision oncology. Case studies from initiatives like the Global Access Program demonstrate successful collaborations between academia, industry, and governments to make essential cancer medications more affordable in LMICs.

Healthcare Workforce Capacity and Training:

- **Challenges:** LMICs often face shortages of skilled healthcare professionals, particularly in specialized fields like oncology. Limited training opportunities and brain drain exacerbate this issue.
- **Opportunities:** Investing in capacity-building initiatives and training programs for healthcare workers can enhance local expertise in oncology care. Case studies from organizations like the American Society of Clinical Oncology (ASCO) demonstrate the effectiveness of mentorship programs and knowledge-sharing platforms in building oncology capacity in LMICs.

Implications for Achieving Equity in Cancer Care Addressing Disparities in Access

- The findings underscore the importance of addressing disparities in access to precision oncology interventions between HICs and LMICs. Efforts to expand access through innovative technologies, cost reduction strategies, and workforce capacity-building initiatives are essential for achieving equity in cancer care.

Collaborative Partnerships

- Collaborative partnerships between governments, academia, industry, and non-profit organizations play a crucial role in overcoming barriers to implementing precision prevention and medicine in LMICs. Case studies highlight the success of such partnerships in driving innovation, reducing costs, and improving healthcare delivery.

Policy and Advocacy

- Policymakers and advocacy groups have a pivotal role in advocating for policies that support the equitable implementation of precision oncology interventions in LMICs. This includes policies to promote technology transfer, incentivize research and development for neglected diseases, and strengthen healthcare systems.

While challenges exist, the results highlight promising opportunities for advancing global oncology towards achieving equity in precision prevention and medicine in LMICs. By addressing barriers to access, fostering collaborative partnerships, and advocating for supportive policies, stakeholders can work towards ensuring that all individuals, regardless of their geographic location or socio-economic status, have access to life-saving cancer treatments.

Discussion

Interpretation in the Context of Existing Literature and Knowledge

Our findings align with existing literature, which underscores the challenges faced by LMICs in accessing precision oncology interventions. The literature emphasizes disparities in healthcare infrastructure, affordability, and workforce capacity as key barriers to implementing precision medicine in these regions. However, our study also highlights promising opportunities for addressing these challenges, drawing insights from case studies and initiatives that have successfully expanded access to precision oncology in LMICs.

Strengths and Limitations of the Study

Strengths

1. **Comprehensive Literature Review:** Our study incorporates findings from a diverse range of scientific articles, reports, and case studies, providing a comprehensive overview of the challenges and opportunities in implementing precision prevention and medicine in LMICs.
2. **Data Synthesis:** By employing qualitative data analysis techniques, we were able to identify recurring themes and patterns within the literature, enhancing the robustness of our findings.

3. **Practical Implications:** The discussion of implications for policy and practice offers actionable insights for stakeholders seeking to address disparities in cancer care.

Limitations

1. **Generalizability:** While our study synthesizes findings from a broad range of sources, the specific challenges and opportunities identified may vary across different LMICs and regions. Therefore, caution should be exercised in generalizing our findings to all LMIC contexts.
2. **Data Availability:** Limited data availability on certain aspects of precision oncology implementation in LMICs may have constrained the depth of our analysis in certain areas.
3. **Bias:** Despite efforts to conduct a comprehensive literature review, our study may be subject to publication bias, as it relies primarily on peer-reviewed articles and reports.

Potential Impact on Policy and Practice

Our findings have significant implications for policymakers, healthcare practitioners, and advocates working to improve cancer care in LMICs:

1. **Policy Implications:** Policymakers can use our findings to inform the development of policies aimed at addressing barriers to access and promoting the equitable implementation of precision oncology interventions. This may include policies to invest in healthcare infrastructure, incentivize technology transfer, and support workforce capacity-building initiatives.
2. **Practice Implications:** Healthcare practitioners can leverage insights from our study to guide the implementation of precision oncology interventions in LMIC settings. This may involve adopting innovative technologies, engaging in collaborative partnerships, and advocating for patient-centered approaches to care delivery.
3. **Advocacy Efforts:** Advocacy groups can use our findings to advocate for increased funding, research, and attention to the unique challenges faced by LMICs in accessing precision oncology. By raising awareness of these issues and mobilizing support, advocates can drive positive change and improve cancer outcomes for populations in need.

Our study contributes to the growing body of evidence on global oncology and underscores the importance of addressing disparities in cancer care to achieve health equity on a global scale.

Conclusion

This paper has examined the impact of advancing global oncology towards achieving equity in cancer care, particularly through precision prevention and medicine in Low- and Middle-Income Countries (LMICs). Key findings from our research highlight the following:

1. **Challenges and Opportunities:** LMICs face significant challenges in accessing precision oncology interventions, including limited healthcare infrastructure, high costs, and workforce capacity constraints. However, innovative solutions and collaborative partnerships offer opportunities to overcome these barriers and expand access to life-saving cancer treatments.
2. **Implications for Equity in Cancer Care:** Addressing disparities in cancer care between HICs and LMICs is essential for achieving health equity globally. Our findings underscore the potential of advancing global oncology to improve access to precision prevention and medicine, thereby narrowing the gap in cancer outcomes between different regions and populations.
3. **Recommendations for Future Research, Policy Changes, and Practical Implementation Strategies**
 - **Future Research:** Further research is needed to explore the effectiveness of specific interventions aimed at expanding access to precision oncology in LMICs. This may include evaluating the impact of technology transfer initiatives, cost reduction strategies, and workforce capacity-building programs on cancer outcomes.
 - **Policy Changes:** Policymakers should prioritize the development and implementation of policies that support the equitable implementation of precision oncology interventions in LMICs. This may involve investing in healthcare infrastructure, incentivizing research and development, and promoting collaboration between stakeholders.
 - **Practical Implementation Strategies:** Healthcare practitioners and organizations can play a crucial role in driving the adoption of precision oncology interventions in LMIC settings. Practical strategies may include leveraging telemedicine and mobile health technologies, fostering partnerships with industry and academia, and advocating for patient-centered approaches to care delivery.
4. Rodin D, *et al.* Innovation for global cancer care: Lessons learnt from the Africa Oxford Cancer Foundation, 2016.
5. Schwaederle M, *et al.* Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trial, 2016.

Advancing global oncology holds immense potential for achieving equity in cancer care worldwide. By addressing barriers to access, fostering collaborative partnerships, and advocating for supportive policies, stakeholders can work together to ensure that all individuals, regardless of their geographic location or socio-economic status, have access to high-quality cancer treatments. Through continued research, policy changes, and practical implementation strategies, we can move closer to realizing this vision of health equity in oncology care.

References

1. Chokunonga E, *et al.* Cancer Survival in Africa, Asia, the Caribbean and Central America (SurvCan), 2016.
2. Ferlay J, *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, 2019.
3. Loehrer PJ, *et al.* Effective Partnerships in Cancer Care: A Community Oncology Perspective, 2017.